Single 4-dose rituximab treatment for low-tumor burden follicular lymphoma (FL):²³ 

• Median PFS: Better in low FLIPI (compared with intermediate or high FLIPI)

• Median PFS: Better in patients achieving molecular clearing of Bcl-2-positive cells by PCR

Standard versus prolonged schedule rituximab (“Swiss-style”): ²¹ 

• Independent prognostic factors for response (include):

  • Diameter < 5 cm

  • Follicular histology (versus mantle cell lymphoma)

  • Normal hemoglobin

  • Low lymphocyte count

• Independent prognostic factors for event-free survival:

  • Responded to induction

  • Stage ≤ III

  • FcγRIII v/v polymorphism

Single 4-dose rituximab treatment in patients previously treated with chemotherapy (multivariate analysis):²² 

• Response to rituximab correlated with:

  • Follicular histology

  • Prior autologous BMT

  • Multi-agent chemotherapy

  • No bone marrow involvement

• Longer TTP and/or DR correlated with:

  • Low/normal serum LDH or Beta-2 microglobulin

  • High CD3-positive cells

  • Response to last chemotherapy